Bruce D. Walker

Last updated

Bruce D. Walker
Bruce 13.jpg
Born (1952-04-18) April 18, 1952 (age 72)
NationalityAmerican
Education
  • University of Colorado, Boulder
  • Case Western Reserve University
  • Mass General Hospital
  • Harvard Medical School
Occupation(s)Physician, scientist
Known forHIV/AIDS research
Website ragoninstitute.org/walker/

Bruce D. Walker (born 1952) is an American physician and scientist whose infectious disease research has produced many findings regarding HIV/AIDS. [1] He became interested in studying HIV/AIDS after practicing on the front lines of the epidemic in the early 1980s, prior to the identification of HIV as the etiologic agent and prior to the availability of viable treatment options. [2]

Contents

An infectious disease specialist and researcher, Walker is the founding director of the Ragon Institute of Mass General, MIT, and Harvard. [1] He is also an investigator at Howard Hughes Medical Institute, an adjunct professor at Nelson R. Mandela School of Medicine at the University of KwaZulu-Natal, and a founding co-director of the Africa Health Research Institute, formerly known as KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH). [3]

He played an active role in COVID-19 research, helping found and co-lead the Massachusetts Consortium on Pathogen Readiness (MassCPR) and advance vaccine development with the Ragon Institute. [4] [5]

Walker was named a Fellow of the American Association for the Advancement of Science in 2004. [6] He was elected to the National Academy of Medicine in 2009. [7]

Early life and education

After graduating from high school, Walker worked as a roofer. He had grown up assuming he would eventually become a scientist and subsequently obtained a bachelor's of science degree in chemistry from the University of Colorado, Boulder. [8] He went on to receive a medical degree from Case Western Reserve University, where he was drawn to clinical medicine. He completed his internship and residency in internal medicine at Mass General Hospital and Harvard Medical School from 1980 to 1983, followed by an internship pathology and fellowship training in infectious disease. [9] He is board certified in both internal medicine and infectious disease. [10] In 1980, as an intern at Mass General Hospital working on the front lines of the still-unidentified HIV/AIDS epidemic, Walker encountered a young man who was admitted to the hospital with multiple simultaneous infections and cancers. This proved to be a sentinel case of a new disease called AIDS, the cause of which was unknown and for which no specific treatment was available. [2] [11]

By the time HIV was identified as the cause of AIDS, Walker and his colleagues had seen many patients with advanced HIV/AIDS, for which few treatment options existed. He has described these experiences as "excruciating" and "heartbreaking." They led Walker to specialize in infectious disease and begin researching HIV in the laboratory, to understand how the body fought back and why it often lost the battle. [2] [12]

Career

Walker has made significant contributions to the research of HIV immune control and immune evasion in HIV infection. [9] [13]

Research into T cell responses and "elite controllers"

In 1987, Walker became among the first researchers, together with his mentors Robert Schooley and Martin Hirsch, to describe HIV-specific CD8+ T cells. [12] [14] Studying persons with HIV infection with grant support from the American Cancer Society, Walker identified extremely robust responses in persons with advanced disease, using recombinant vaccinia viruses to express HIV proteins. [14] [15]

Before effective antiretroviral therapy was available, Walker met a patient with hemophilia who had been infected with HIV through a blood product in 1978 but never developed AIDS. At first, Walker did not believe the patient had HIV because he had remained healthy despite being infected for 17 years, as confirmed by the patient's years of stored blood samples. This experience initiated a career of learning from patients, inspiring subsequent research into "elite controllers," the less than 1 percent of people living with HIV who remain healthy, without medication, decades after infection. [16] Studying these individuals has been a major focus of Walker's research efforts, leading to the discovery of HIV-specific CD4+ T cells. [17]

In South Africa, Walker has worked with Drs. Krista Dong, Thumbi Ndung'u, and collaborators to focus on hyperacute HIV infection. They perform their work through a cohort called FRESH, meaning, "Females Rising through Education, Support, and Health." FRESH is a program that combines HIV prevention, a pathway out of poverty for young women at high risk, and a study of hyperacute HIV infection. [18] [19] One goal of the program is to ward off HIV infections through a prevention curriculum that includes life skills training, empowerment skills, computer education, HIV prevention education, PrEP (pre-exposure prophylaxis), and job readiness training. Organizers aspire to help participants find employment after nine months in the program. The second goal is to identify persons in the window period before peak viremia and seroconversion (defined by Fiebig Stages I-VI), to determine how the battle between host and virus begins. [18] [19] Through this study, Walker and colleagues have determined that the higher initial magnitude of the HIV-specific T cell response, the lower the viral set point in untreated infection. [20] They also found that immediate treatment leads to more functional immune responses. [21]

Doris Duke Medical Research Institute (DDMRI) and the Africa Health Research Institute

In 1998, Walker began research in KwaZulu-Natal (KZN) province, South Africa. The initial plan had been to find collaborators in South Africa, hardest hit by the AIDS epidemic, to study immune responses in babies born with HIV infection, who typically have very rapid disease progression. The stated goal was to bring samples back to the US, but the African collaborators, led by the late Jerry Coovadia, asked Walker and colleagues to consider doing the studies in Durban and teach them to conduct fundamental research. This prompted the establishment of a small laboratory at the University of KwaZulu Natal (UKZN) in Durban. [22] Recognizing the wealth of knowledge that could be gained by conducting research at the heart of the TB and HIV epidemics, as well as the need for capacity building for fundamental and translational research, [23] Walker, Coovadia, Salim Abdool Karim, and Philip Goulder initiated a plan to build a research laboratory at the University, which had not had a new building built in over 50 years. In 2003, the Doris Duke Medical Research Institute (DDMRI) opened at the Nelson R. Mandela School of Medicine. The institute was largely funded through a Doris Duke Charitable Foundation Walker had received at MGH. UKZN took ownership of the new facility. [24]

In 2012, the research facilities there were expanded to include the KwaZulu-Natal Research Institute for TB and HIV (K-RITH), funded by Walker's employer the Howard Hughes Medical Institute and for which Walker served as a founding co-director. [25] K-RITH has subsequently been renamed the Africa Health Research Institute. [26]

Ragon Institute of Mass General, MIT, and Harvard

The Ragon Institute of Mass General, MIT, and Harvard was officially established in 2009, with the support of Phillip Ragon and his wife, Susan M. Ragon. Walker met Phillip Ragon at the request of a salesman for an electronic medical record (EMR) being used at a mission hospital where Walker and collaborators were working to treat persons living with HIV. Ragon's company, InterSystems, had just acquired the EMR, and the salesman wanted Walker to convey how important the EMR was for treatment of persons living with HIV. This led to a brief conversation between Walker and Ragon, followed by a short trip to KZN to see the EMR in action and to get a view of the ongoing HIV epidemic. After three days, Ragon asked how he could help. In the end, he and Susan Ragon donated $100 million in 2009 to establish the Ragon Institute, whose vision is to harness the immune system to prevent and cure human disease. The foundations of the Institute began with HIV research in South Africa, [27] and HIV remains one of the institute's primary areas of focus. [28] During the organization's first two years, Walker brought on 40 new scientists to research HIV. [22] Walker works as a principal investigator at the Ragon Institute and focuses with his team on the body's immune response to viral infection, [1] including through studies of patients with chronic HIV infection and those who can control HIV infection to undetectable levels without the need for antiretroviral therapy (ART). [16] [29]

Research work and career highlights

Awards and recognition

The following are awards and honors bestowed upon Walker:

Related Research Articles

<span class="mw-page-title-main">HIV</span> Human retrovirus, cause of AIDS

The human immunodeficiency viruses (HIV) are two species of Lentivirus that infect humans. Over time, they cause acquired immunodeficiency syndrome (AIDS), a condition in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, the average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype.

<span class="mw-page-title-main">HIV/AIDS in the United States</span> HIV/AIDS epidemic in the United States

The AIDS epidemic, caused by HIV, found its way to the United States between the 1970s and 1980s, but was first noticed after doctors discovered clusters of Kaposi's sarcoma and pneumocystis pneumonia in homosexual men in Los Angeles, New York City, and San Francisco in 1981. Treatment of HIV/AIDS is primarily via the use of multiple antiretroviral drugs, and education programs to help people avoid infection.

<span class="mw-page-title-main">HIV vaccine development</span> In-progress vaccinations that may prevent or treat HIV infections

An HIV vaccine is a potential vaccine that could be either a preventive vaccine or a therapeutic vaccine, which means it would either protect individuals from being infected with HIV or treat HIV-infected individuals.

<span class="mw-page-title-main">David Ho</span> Asian-American physician and scientist

David Da-i Ho is a Taiwanese American AIDS researcher, physician and virologist who has made a number of scientific contributions to the understanding and treatment of HIV infection. He championed for combination anti-retroviral therapy instead of single therapy, which turned HIV from an absolute terminal disease into a chronic disease.

<span class="mw-page-title-main">Stanley Plotkin</span> American physician

Stanley Alan Plotkin is an American physician who works as a consultant to vaccine manufacturers, such as Sanofi Pasteur, as well as biotechnology firms, non-profits and governments. In the 1960s, he played a pivotal role in discovery of a vaccine against rubella virus while working at Wistar Institute in Philadelphia. Plotkin was a member of Wistar’s active research faculty from 1960 to 1991. Today, in addition to his emeritus appointment at Wistar, he is emeritus professor of Pediatrics at the University of Pennsylvania. His book, Vaccines, is the standard reference on the subject. He is an editor with Clinical and Vaccine Immunology, which is published by the American Society for Microbiology in Washington, D.C.

This is a timeline of HIV/AIDS, including but not limited to cases before 1980.

<span class="mw-page-title-main">History of HIV/AIDS</span>

AIDS is caused by a human immunodeficiency virus (HIV), which originated in non-human primates in Central and West Africa. While various sub-groups of the virus acquired human infectivity at different times, the present pandemic had its origins in the emergence of one specific strain – HIV-1 subgroup M – in Léopoldville in the Belgian Congo in the 1920s.

<span class="mw-page-title-main">HIV/AIDS</span> Spectrum of conditions caused by HIV infection

The human immunodeficiency virus (HIV) is a retrovirus that attacks the immune system. It can be managed with treatment. Without treatment it can lead to a spectrum of conditions including acquired immunodeficiency syndrome (AIDS).

<span class="mw-page-title-main">Robert Gallo</span> American biomedical researcher

Robert Charles Gallo is an American biomedical researcher. He is best known for his role in establishing the human immunodeficiency virus (HIV) as the infectious agent responsible for acquired immune deficiency syndrome (AIDS) and in the development of the HIV blood test, and he has been a major contributor to subsequent HIV research.

<span class="mw-page-title-main">Françoise Barré-Sinoussi</span> French virologist and Nobel laureate (born 1947)

Françoise Barré-Sinoussi is a French virologist and Director of the Regulation of Retroviral Infections Division and Professor at the Institut Pasteur in Paris. Born in Paris, Barré-Sinoussi performed some of the fundamental work in the identification of the human immunodeficiency virus (HIV) as the cause of AIDS. In 2008, Barré-Sinoussi was awarded the Nobel Prize in Physiology or Medicine, together with her former mentor, Luc Montagnier, for their discovery of HIV. She mandatorily retired from active research on 31 August 2015, and fully retired by some time in 2017.

Phillip T. and Susan M. Ragon Institute is a medical institute founded in 2009 at the Massachusetts General Hospital (MGH) by the funding from founder and CEO of InterSystems Phillip Ragon and his wife Susan Ragon to find vaccines for diseases of the immune system, particularly HIV/AIDS. The institute includes scientists from Harvard University, the Massachusetts Institute of Technology (MIT) and the MGH, a level I trauma center which is the largest teaching hospital affiliated with Harvard Medical School.

<span class="mw-page-title-main">Gladstone Institutes</span>

Gladstone Institutes is an independent, non-profit biomedical research organization whose focus is to better understand, prevent, treat and cure cardiovascular, viral and neurological conditions such as heart failure, HIV/AIDS and Alzheimer's disease. Its researchers study these diseases using techniques of basic and translational science. Another focus at Gladstone is building on the development of induced pluripotent stem cell technology by one of its investigators, 2012 Nobel Laureate Shinya Yamanaka, to improve drug discovery, personalized medicine and tissue regeneration.

Thumbi Ndung’u is a Kenyan-born HIV/AIDS researcher. He is the deputy director (Science) and a Max Planck Research Group Leader at the Africa Health Research Institute (AHRI) in Durban, South Africa. He is Professor of Infectious Diseases in the Division of Immunity and Infection, University College London. He is Professor and Victor Daitz Chair in HIV/TB Research and Scientific Director of the HIV Pathogenesis Programme (HPP) at the Nelson R. Mandela School of Medicine, University of KwaZulu-Natal. He holds the South African Research Chair in Systems Biology of HIV/AIDS. He is an Adjunct Professor of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health. He is the Programme Director of the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a research and capacity building initiative funded by the African Academy of Sciences and the Wellcome Trust.

<span class="mw-page-title-main">HIV/AIDS research</span> Field of immunology research

HIV/AIDS research includes all medical research that attempts to prevent, treat, or cure HIV/AIDS, as well as fundamental research about the nature of HIV as an infectious agent and AIDS as the disease caused by HIV.

<span class="mw-page-title-main">Hendrik Streeck</span> German virologist

Hendrik Streeck is a German researcher of human immunodeficiency virus, epidemiologist and clinical trialist. He is professor of virology and the director of the Institute of Virology and HIV Research at the University Bonn.

Marylyn Martina Addo is a German infectiologist who is a Professor and the German Center for Infection Research (DZIF) Head of Infectious Disease at the University Medical Center Hamburg-Eppendorf. Addo has developed and tested vaccinations that protect people from Ebola virus disease and the MERS coronavirus EMC/2012. She is currently developing a viral vector based COVID-19 vaccine.

<span class="mw-page-title-main">Todd M. Allen</span> Canadian-born immunologist and virologist

Todd Mackenzie Allen is a Canadian-born immunologist and virologist at the Ragon Institute of MGH, MIT and Harvard, and a Professor of Medicine at Harvard University. He is a specialist in HIV vaccine design and the sequence evolution and diversity of HIV and hepatitis C virus (HCV). More recently, his work is focused on developing novel immunotherapeutic approaches towards a functional cure of HIV, including chimeric antigen receptor (CAR) T cell immunotherapy and gene editing approaches capable of protecting against HIV infection.

Catherine Wilfert was an American pediatrician specializing in infectious diseases. She became a professor at Duke University School of Medicine and known internationally for her work in pediatric HIV prevention. After 1993, using zidovudine during pregnancy led to an estimated reduction of mother-to-infant transmission of HIV in the United States by 75 percent and a 47 percent decrease in new HIV infections globally.

<span class="mw-page-title-main">Alex K. Shalek</span> Biomedical engineer

Alex K. Shalek is a biomedical engineer, and a core faculty member of the Institute for Medical Engineering and Science (IMES), an Associate Professor of Chemistry, and an Extramural Member of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. Additionally, he is a Member of the Ragon Institute and an Institute Member of the Broad Institute, an Assistant in Immunology at Massachusetts General Hospital, and an Instructor in Health Sciences and Technology at Harvard Medical School. The multi-disciplinary research of the Shalek Lab aims to create and implement broadly-applicable methods to study and engineer cellular responses in tissues, to drive biological discovery and improve prognostics, diagnostics, and therapeutics for autoimmune, infectious, and cancerous diseases. Shalek and his lab are best known for their work in single-cell genomics and for studying a number of devastating, but difficult to study, human diseases with partners around the world.

Galit Alter is an immunologist and virologist, professor of medicine at Harvard Medical School, and group leader at the Ragon Institute of MGH, MIT and Harvard. She is known for her work on the expansion of particular natural killer cell subtypes in response to HIV-1 infection. She has also contributed to the understanding of how SARS-CoV-2 antibody titers correlate with sustained humoral protection, including identifying coordinated immune cell-antibody signatures that may predict COVID-19 infection outcome.

References

  1. 1 2 3 4 5 6 "Walker - Ragon Institute of Mass General, MIT, and Harvard". Walker. Archived from the original on November 6, 2023. Retrieved November 6, 2023.
  2. 1 2 3 Neel, Dylan (February 7, 2023). "Lab Meeting: Bruce Walker". Biomarker. Archived from the original on November 6, 2023. Retrieved November 6, 2023.
  3. ↑ "Bruce D. Walker, MD | Investigator Profile | 2002-Present | HHMI". www.hhmi.org. Archived from the original on November 6, 2023. Retrieved November 6, 2023.
  4. 1 2 Couzin-Frankel, Jennifer (March 5, 2020). "With $115 million, more than 80 Boston researchers will collaborate to tackle COVID-19". Science. Archived from the original on November 6, 2023. Retrieved November 6, 2023.
  5. 1 2 Narayanan, Srinidhi (April 15, 2021). "MIT hosts COVID-19 vaccine webinar with Harvard and Ragon Institute". The Tech. Archived from the original on November 6, 2023. Retrieved November 6, 2023.
  6. ↑ "Faculty, alumni named AAAS fellows". Case Western Reserve University. November 15, 2004. Archived from the original on February 14, 2016. Retrieved March 13, 2016.
  7. ↑ "Bruce D. Walker, M.D." National Academy of Medicine . Retrieved March 13, 2016.[ permanent dead link ]
  8. ↑ "The Realm of Possibility | Understanding How the Body Fights HIV Infection". Archived from the original on November 8, 2023. Retrieved November 8, 2023.
  9. 1 2 "Bruce Walker, MD". CHAVD. Archived from the original on November 8, 2023. Retrieved November 8, 2023.
  10. ↑ "Dr. Bruce D. Walker". U.S. News & World Report. Archived from the original on November 8, 2023. Retrieved November 8, 2023.
  11. ↑ "The AIDS Epidemic in the United States, 1981-early 1990s | David J. Sencer CDC Museum | CDC". www.cdc.gov. April 29, 2021. Archived from the original on December 8, 2023. Retrieved November 8, 2023.
  12. 1 2 3 Archives, L. A. Times (July 23, 1987). "Cell That Destroys AIDS Virus Discovered". Los Angeles Times. Archived from the original on November 8, 2023. Retrieved November 8, 2023.
  13. 1 2 "Bruce D. Walker". Research.com. Archived from the original on November 14, 2023. Retrieved November 14, 2023.
  14. 1 2 Walker, Bruce D.; Chakrabarti, Sekhar; Moss, Bernard; Paradis, Timothy J.; Flynn, Theresa; Durno, Amy G.; Blumberg, Richard S.; Kaplan, Joan C.; Hirsch, Martin S.; Schooley, Robert T. (July 1987). "HIV-specific cytotoxic T lymphocytes in seropositive individuals". Nature. 328 (6128): 345–348. Bibcode:1987Natur.328..345W. doi:10.1038/328345a0. ISSN   1476-4687. PMID   3496541. S2CID   4238505. Archived from the original on November 14, 2023. Retrieved November 14, 2023.
  15. ↑ Walker, Bruce D.; Flexner, Charles; Paradis, Timothy J.; Fuller, Thomas C.; Hirsch, Martin S.; Schooley, Robert T.; Moss, Bernard (April 1988). "HIV-1 Reverse Transcriptase Is a Target for Cytotoxic T Lymphocytes in Infected Individuals". Science. 240 (4848): 64–66. Bibcode:1988Sci...240...64W. doi:10.1126/science.2451288. ISSN   0036-8075. PMID   2451288. Archived from the original on November 14, 2023. Retrieved November 14, 2023.
  16. 1 2 Shaw, Jonathan (January 2019). "People Who Don't Get AIDS". Harvard Magazine. Archived from the original on November 14, 2023. Retrieved November 14, 2023.
  17. ↑ "Special Type of Immune Cell May Be Key to Avoiding AIDS". The New York Times. November 21, 1997. pp. Section A, Page 18. Archived from the original on November 14, 2023. Retrieved November 14, 2023.
  18. 1 2 3 Ndung'u, Thumbi; Dong, Krista L.; Kwon, Douglas S.; Walker, Bruce D. (September 21, 2018). "A FRESH approach: Combining basic science and social good". Science Immunology. 3 (27). doi:10.1126/sciimmunol.aau2798. ISSN   2470-9468. PMC   7593829 . PMID   30217812.
  19. 1 2 3 Parsons, Lian (September 19, 2019). "Ragon Institute receives major gift to expand research into autoimmune diseases". Harvard Gazette. Archived from the original on November 14, 2023. Retrieved November 14, 2023.
  20. ↑ Ndhlovu, Zaza; Kamya, Philomena; Dong, Krista; Ndung'u, Thumbi; Walker, Bruce (September 15, 2015). "Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point". Immunity. 43 (3): 591–604. doi: 10.1016/j.immuni.2015.08.012 . PMC   4575777 . PMID   26362266.
  21. ↑ Ndhlovu, Zaza M.; Kazer, Samuel W.; Nkosi, Thandeka; Ogunshola, Funsho; Muema, Daniel M.; Anmole, Gursev; Swann, Shayda A.; Moodley, Amber; Dong, Krista; Reddy, Tarylee; Brockman, Mark A.; Shalek, Alex K.; Ndung'u, Thumbi; Walker, Bruce D. (May 22, 2019). "Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection". Science Translational Medicine. 11 (493). doi:10.1126/scitranslmed.aau0528. ISSN   1946-6234. PMC   6901350 . PMID   31118290.
  22. 1 2 Kresge, Kristen Jill; McEnery, Regina (July–August 2011). "The House that Bruce Built" (PDF). IAVIReport. pp. 4–11. Archived (PDF) from the original on November 19, 2023. Retrieved November 19, 2023.
  23. ↑ Goulder, P. J.; Brander, C.; Tang, Y.; Tremblay, C.; Colbert, R. A.; Addo, M. M.; Rosenberg, E. S.; Nguyen, T.; Allen, R.; Trocha, A.; Altfeld, M.; He, S.; Bunce, M.; Funkhouser, R.; Pelton, S. I. (July 19, 2001). "Evolution and transmission of stable CTL escape mutations in HIV infection". Nature. 412 (6844): 334–338. doi:10.1038/35085576. ISSN   0028-0836. PMID   11460164. S2CID   4332431. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
  24. 1 2 Lok, Corie (May 26, 2011). "His Best Shot: Can Bruce Walker transform HIV vaccine research?" (PDF). Nature. 473 (7348): 439–441. doi:10.1038/473439a. PMID   21614054. Archived (PDF) from the original on January 17, 2024. Retrieved November 19, 2023.
  25. ↑ "K-RITH Brings Exceptional TB and HIV Research Capabilities to Durban and the World | HHMI". www.hhmi.org. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
  26. ↑ Pillay, Deenan (July 18, 2016). "Scientists are combining forces to tackle the deadly duo of TB and HIV". The Conversation. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
  27. 1 2 Bartlett, Jessica (April 29, 2019). "Here's how a chance visit led to the largest philanthropic gift in MGH history". Boston Business Journal . Archived from the original on November 9, 2023. Retrieved May 24, 2024.
  28. ↑ Rosado, Gloria (July 28, 2020). "Five Things to Know About the Ragon Institute". Bench Press. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
  29. ↑ O'Sullivan, Dan (June 4, 2019). "Ragon Institute: Harnessing the Power of Human Immunity". Massachusetts General Hospital. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
  30. 1 2 "Bruce David Walker". dms.hms.harvard.edu. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
  31. ↑ "Bruce Walker". MIT Department of Biology. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
  32. ↑ "About Us". masscpr.hms.harvard.edu. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
  33. ↑ "New HST.S46 IAP course "Evolution of an Epidemic" takes MIT undergrads to the heart of the AIDS epidemic in Africa". Harvard-MIT Health Sciences and Technology. March 27, 2017. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
  34. ↑ Smith, Brianna (May 16, 2023). "Celebrating our graduates: Commencement events to be held throughout the week for the Class of 2023". The Daily. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
  35. 1 2 "Bruce Walker". Institute for Medical Engineering & Science. August 29, 2022. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
  36. ↑ "Dr. Bruce D. Walker". National Academy of Medicine. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
  37. ↑ "Bruce D. Walker". American Academy of Arts & Sciences. October 18, 2023. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
  38. ↑ "AID FOR AIDS International - My Hero Gala". Musée Magazine. November 12, 2012. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
  39. ↑ "AIDS Walk & Run Boston Raises $750,000 to Support Work to End HIV/AIDS in MA". The Rainbow Times. Boston. June 6, 2017. Archived from the original on November 19, 2023. Retrieved November 19, 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.